echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NEJM: Redsywee shortens recovery time for patients with neocyctic pneumonia.

    NEJM: Redsywee shortens recovery time for patients with neocyctic pneumonia.

    • Last Update: 2020-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    There is currently no effective treatment for Coronary Viral Disease (Covid-19) in 2019, and Redsyvir is once the industry's most highly expected drug.
    recently published the final results of a clinical study of Redsiway's treatment of new coronary pneumonia.
    In this double-blind, randomized, placebo-controlled study, researchers recruited adult patients hospitalized with Covid-19 with lower respiratory tract infections to be randomly intravenously injected with Redsywe (200 mg on the first day of load, followed by a daily therapeutic dose of 100 mg for up to 9 days) or a placebo.
    result of this study is recovery time, defined as discharge or hospitalization for infection control purposes only.
    1,062 patients were involved in the study, including 541 in the Redsiway group and 521 in the placebo group.
    recovery time for patients receiving Redsyve treatment was 10 days, while for patients receiving placebo was 15 days (recovery rate was 1.29).
    analysis showed that patients treated with Redsiway were more likely to experience clinical improvement on the 15th day (the actual disease severity-adjusted advantage was 1.5) than placebo.
    survival analysis showed a 15-day mortality rate of 6.7 per cent in the Redsyway group, 11.9 per cent in the placebo group, 11.4 per cent on the 29th day in the Redsyve group and 15.2 per cent in the placebo (risk ratio of 0.73).
    131 (24.6%) of the 532 patients treated with Redsiway reported serious adverse events, and 163 (31.6%) of the 516 patients treated with placebo reported serious adverse events.
    that in patients with new coronary pneumonia with evidence of lower respiratory tract infections, redsiway therapy is beneficial in reducing recovery time.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.